HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00600236

Enrollment

Registered

2008-01-24

Start date

2004-09-30

Completion date

2008-01-31

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 2, Proliferative Diabetic Retinopathy

Keywords

Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy, Diabetes mellitus type 2 with 10 years of diagnosis and proliferative diabetic retinopathy

Brief summary

One of the first causes of irreversible blindness in mexican population is diabetic retinopathy which is clearly diferent between patients the time of evolution and development of retinopathy and complications. The aim of this study is to explore the inmunogenetic profile and the influence of HLA in this variations of the sickness to predict the severity of diabetic complications.

Interventions

PROCEDUREblood sample

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy * Diabetes mellitus type 2 with 10 years of diagnosis and proliferative retinopathy

Exclusion criteria

* Systemic hipertension * Cardic disease * Lupus * Any kind of artritis * Allergies * Optic Neuritis * VKH * Cancer * Inmunological diseases

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026